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Abstract
Coronary heart disease is the single most common 
cause of illness and death in the developed world. 
Coronary atherosclerosis is by far the most frequent 
cause of ischemic heart disease, and plaque disruption 
with superimposed thrombosis is the main cause of the 
acute coronary syndromes of unstable angina, myocar-
dial infarction, and sudden death. Atherosclerosis is the 
result of a complex interaction between blood elements, 
disturbed flow, and vessel wall abnormality, involving 
several pathological processes: inflammation, with in-
creased endothelial permeability, endothelial activation, 
and monocyte recruitment; growth, with smooth muscle 
cell proliferation, migration, and matrix synthesis; de-
generation, with lipid accumulation; necrosis, possibly 
related to the cytotoxic effect of oxidized lipid; calcifica-
tion/ossification, which may represent an active rather 
than a dystrophic process; and thrombosis, with platelet 
recruitment and fibrin formation. In this review we dis-
cuss these processes and the possible pathological ef-
fects of Chlamydia  infection and the ensuing phlogosis.
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INTRODUCTION
Approximately one third of  patients with coronary ar-
tery disease (CAD) do not have traditional risk factors. 
New evidence shows that systemic markers of  inflam-
mation are a strong predictor of  cardiovascular events, 
adding independently to traditional risk factors. Inflam-
mation systemically or locally within an atherosclerotic 
plaque is believed to play a major role in the initiation 
and progression of  CAD and the precipitation of  acute 
coronary events. Cardiovascular events may most com-
monly arise from sites of  “nonsignificant” stenosis, sug-
gesting that plaque instability rather than the degree of  
stenosis is the key risk factor. This plaque instability is 
believed related to inflammation within the plaque, with 
activated macrophages releasing inflammatory media-
tors, activating matrix metalloproteinases (MMP), and 
breaking down the protective fibrous cap. Sources of  
this inflammation may include non-infectious triggers 
[e.g. oxidized low-density lipoprotein (LDL), oxidation 
products of  smoking, endothelial injury, genetics, etc.] or 
a number of  proposed infectious triggers[1-9].
Currently, it is known that local and systemic inflam-
matory processes play an important role in the genesis 
and development of  atherosclerotic lesions and in the 
pathophysiology of  acute coronary syndromes. This hy-
pothesis is supported by findings of  elevated parameters 
of  the inflammatory reaction in the blood of  athero-
sclerotic patients as well as findings of  histopathological 
characteristics of  unstable plaques (thin fibrous cap, 
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large necrotic core, less smooth muscle cells and abun-
dant foamy cells and lymphocytes). Furthermore, sev-
eral studies have demonstrated that inflammation has a 
determining role in the rupture of  the coronary plaque, 
and investigations have been carried out to identify the 
etiopathogenetic basis of  the inflammation itself, trying 
to correlate coronary atherosclerosis and its develop-
ment with some infectious agents[7-12].
Potentially, acute or chronic infections could initiate 
and promote CAD in the absence of  traditional risk fac-
tors. More likely, infections act to augment CAD risk in 
the presence of  other risk factors. A number of  mecha-
nisms have been proposed which could link infection to 
atherosclerosis[10].
Understanding the pathogenesis of  atherosclerosis and 
the role of  inflammation first requires some knowledge 
of  the structure and biology of  the normal artery and its 
indigenous cell types.
ANATOMY
Normal arteries have a well-developed trilaminar struc-
ture. The innermost layer, the tunica intima, is a mon-
olayer of  endothelial cells abutting directly on a basal 
lamina and constitutes the crucial contact surface with 
blood. Arterial endothelial cells possess many highly 
regulated mechanisms of  capital importance for vascular 
homeostasis that often go awry during the pathogenesis 
of  arterial diseases. The internal elastic membrane serves 
as the border between the intimal layer and the underly-
ing tunica media[8-12]. The media of  elastic arteries such 
as the aorta have well-developed concentric layers of  
smooth muscle cells, interleaved with layers of  elastin-
rich extracellular matrix. This structure appears well 
adapted for the storage of  the kinetic energy of  left ven-
tricular systole by the walls of  great arteries. The lamel-
lar structure also doubtless contributes to the structural 
integrity of  the arterial trunks. In the media of  smaller 
muscular arteries there are usually smooth muscle cells 
residing within the surrounding matrix in a more contin-
uous manner than in lamellar array. In the normal artery 
the smooth muscle cells are generally quiescent from 
the standpoint of  growth control and there is a state of  
homeostasis of  extracellular matrix. The external elastic 
lamina forms a border with the adventitial layer. The 
adventitia contains collagen fibrils and a cellular popula-
tion such as fibroblasts and mast cells. Vasa vasorum 
and nerve endings localize in this outermost layer of  the 
arterial wall[12-15]. 
PATHOPHYSIOLOGY
The pathogenesis of  atherogenesis and of  its devel-
opment remain largely conjectural. One of  the first 
ultrastructural alterations is an accumulation of  small 
lipoprotein particles (LDL) in the intima, where bind-
ing of  lipoproteins to proteoglycan occurs which tends 
to coalesce into aggregates. This process is supported 
by permeability of  the endothelial monolayer. Lipopro-
tein particles bound to proteoglycan appear to exhibit 
increased susceptibility to oxidative or other chemical 
modifications such as enzymatic processing and glyca-
tion which can modify LDL in the intima. The second 
morphologically definable event in the initiation of  
atheroma is leukocyte recruitment and accumulation; 
these adhere to the endothelium by means of  adhesion 
molecules, and diapedese between endothelial cell junc-
tions to enter the intima, where they begin to accumulate 
lipids and transform into foam cells. In addition to the 
monocytes, T lymphocytes also tend to accumulate in 
early atherosclerotic lesions. The current concept of  
directed migration of  leukocytes involves the action of  
protein molecules known as chemoattractant cytokines, 
or chemokines, produced by the endothelium and 
smooth muscle in response to oxidized lipoprotein and 
other stimuli[16-19].
Until now the natural history of  the atherosclerotic 
process has not been totally understood. Some research-
ers have invoked a multicentric origin hypothesis of  
atherogenesis, positing that atheromas arise as benign 
leiomyomas of  the artery wall. However, the location 
of  sites of  lesion predilection at proximal portions of  
arteries after branch points or bifurcations at flow di-
viders suggests a hydrodynamic basis for early lesion 
development. Locally disturbed flow could induce al-
terations that promote the steps of  early atherogenesis; 
alternatively, the laminar flow may elicit antiatherogenic 
homeostatic mechanisms (atheroprotective functions). 
This hypothesis is supported by in vitro data suggesting 
that laminar shear stress can augment the expression of  
genes that may protect against atherosclerosis, including 
forms of  the enzymes superoxide dismutase (which re-
duces oxidative stress by catabolizing the reactive and in-
jurious superoxide anion) or nitric oxide synthase (which 
produces nitric oxide, an endogenous vasodilator and 
anti-inflammatory agent)[19,20].
Whereas the early events in atheroma initiation in-
volve primarily altered endothelial function and recruit-
ment and accumulation of  leukocytes, the subsequent 
evolution of  atheroma into more complex plaques ad-
ditionally involves smooth muscle cells. Some smooth 
muscle cells likely migrate from the underlying media 
into the intima, attracted by molecules such as platelet-
derived growth factor, secreted by activated macro-
phages and overexpressed in atherosclerosis. These 
smooth muscle cells begin to replication themselves; 
furthermore, death of  these cells may also participate 
in complications of  the atherosclerotic plaque. The vas-
cular smooth muscle cell produces extracellular matrix 
molecules which make up much of  the volume of  an 
advanced atherosclerotic plaque. This matrix is catalyzed 
in part by enzymes known as MMP. This dissolution also 
likely plays a role in the arterial remodeling that accom-
panies lesion growth. During the first part of  the life 
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history of  an atheromatous lesion, growth of  the plaque 
is outward, in an abluminal direction, rather than inward. 
The smooth muscle cell is not alone in its proliferation 
and migration within the evolving atherosclerotic plaque. 
Endothelial cell migration and replication also occur as 
plaques develop in microcirculation, characterized by 
plexuses of  newly formed vessels. The microvasculari-
zation of  plaques may also allow growth of  the plaque, 
overcoming diffusion limitations on oxygen and nutrient 
supply. Finally, the plaque microvessels may be friable 
and prone to rupture. Hemorrhage and thrombosis in situ 
could promote a local cycle of  smooth muscle cell prolif-
eration and matrix accumulation in the area immediately 
adjacent to the microvascular disruption. Plaques often 
develop areas of  calcification as they evolve[21-23].
The process of  initiation and evolution of  the athero-
sclerotic plaque generally takes place over many years, 
during which the affected person often has no symptoms. 
After the plaque burden exceeds the capacity of  the 
artery to remodel outward, encroachment on the arte-
rial lumen begins. Eventually the stenosis may progress 
to a degree that impedes blood flow through the artery. 
The development of  chronic stable angina pectoris or 
intermittent claudication on increased demand is a com-
mon presentation of  this type of  atherosclerotic disease. 
However, several kinds of  clinical observation suggest 
that most myocardial infarctions result not from critical 
blockages but from lesions that produce stenoses which 
do not limit flow. Instead of  progressive growth of  the 
intimal lesion to a critical stenosis, we now recognize 
that thrombosis, complicating a not necessarily occlusive 
plaque, most often causes episodes of  unstable angina 
or acute myocardial infarction. Thrombosis is the conse-
quence of  a fracture of  the plaque’s fibrous cap, or of  a 
superficial erosion of  the intima[24-28].
RISK FACTORS
The “risk factor” is a characteristic or feature of  an in-
dividual or population that is present early in life which 
is associated with an increased risk of  developing future 
cardiovascular disease. The risk factor of  interest may be 
a behavior (e.g. smoking), an inherited trait (e.g. family 
history), or a laboratory measurement (e.g. cholesterol). 
Features can be classified as conventional atherosclerotic 
risk factors such as hyperlipidemia, smoking, hyperten-
sion, insulin resistance and diabetes, physical activity, 
obesity, and hormone status; or novel atherosclerotic risk 
factors, including levels of  homocysteine, fibrinogen, 
lipoprotein(a) [Lp(a)], as well as infective agents, markers 
of  inflammation [e.g. high-sensitivity C-reactive protein 
(CRP)], indices of  fibrinolytic function [e.g. tissue-type 
plasminogen activator (t-PA) and plasminogen activator 
inhibitor 1 (PAI-1)][10,14,25].
Dyslipidemia
Dyslipidemia encompasses disorders that include high 
average total plasma cholesterol levels, particularly LDL, 
but low high-density lipoproteins (HDL). Several stud-
ies point out the relationship between LDL and possibly 
very LDL and CAD. The role of  HDL as a protective 
fraction has also emerged. Cholesterol (C) plays an im-
portant role in the atherosclerotic process, as it actually 
is a main constituent of  the plaque. Furthermore, the 
presence of  small, dense LDL particles may be related 
to features of  the “metabolic syndrome”, characterized 
by the presence of  abdominal obesity, peripheral insulin 
resistance, high blood pressure, and a dyslipoproteinemia 
with elevated plasma triglycerides and reduced HDL-C 
levels[21-26].
Smoking
Cigarette consumption constitutes the single most im-
portant modifiable risk factor for CAD. Smoking affects 
atherothrombosis via several mechanisms. In addition 
to accelerating atherosclerotic progression, long-term 
smoking may enhance oxidation of  LDL-C and reduce 
levels of  HDL-C. Smoking also impairs endothelium-
dependent coronary artery vasodilation and has multiple 
adverse hemostatic effects; it actually increases inflam-
matory markers such as CRP, soluble intercellular adhe-
sion molecule (ICAM-1), and fibrinogen, causes spon-
taneous platelet aggregation and increases monocyte 
adhesion to endothelial cells[26].
Hypertension
Hypertension is often a silent cardiovascular risk factor. 
The risk increases in the presence of  other cardiovas-
cular risk factors such as insulin resistance and obesity. 
This cluster of  metabolic and cardiovascular risk factors 
is named “Metabolic Syndrome” and also includes dysli-
pidemia, prothrombotic state and inflammatory state[27].
Insulin resistance and diabetes
Diabetic patients have a greater atherosclerotic burden 
both in the major arteries and in the microvascular circu-
lation. Insulin resistance also produces a prothrombotic 
state due to increased levels of  PAI-1 and fibrinogen. In 
addition to these systemic metabolic abnormalities, hy-
perglycemia causes accumulation of  advanced glycation 
end products inculpated in vascular damage. Further-
more, diabetic patients have markedly impaired endothe-
lial and smooth muscle function and appear to have 
increased leukocyte adhesion to vascular endothelium, a 
critical early step in atherogenesis[28].
Exercise and obesity
Regular physical exercise reduces myocardial oxygen 
demand and increases exercise capacity, both of  which 
are associated with lower levels of  coronary risk. The 
mechanisms by which exercise lowers cardiovascular 
risk remain uncertain but likely include favorable effects 
on blood pressure, weight control, lipid profiles, and 
improved glucose tolerance. Exercise also improves 
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endothelial function, enhances fibrinolysis, reduces 
platelet reactivity, and reduces propensity for in situ 
thrombosis.
Controversy remains as to whether obesity itself  is 
a true risk factor for cardiovascular disease or whether 
its impact on vascular risk is mediated solely through 
interrelations with glucose intolerance, insulin resistance, 
hypertension, physical inactivity, and dyslipidemia[28,29].
Mental stress
The adrenergic stimulation of  mental stress can clearly 
augment myocardial oxygen requirements, can cause 
coronary vasoconstriction, particularly in atherosclerotic 
coronary arteries, and hence can also influence myocar-
dial oxygen supply. Catecholamines can also promote 
alterations in thrombosis[30].
Estrogen status
Before the menopause, women have lower age-adjusted 
incidence and mortality rates for coronary heart disease 
than men. This effect results from the beneficial actions 
of  estrogen on lipid fractions, but is also due to direct 
vascular mechanisms such as improved endothelial-
dependent vasomotion, reduced LDL oxidation, altered 
adhesion molecule levels, increased fibrinolytic capacity, 
and enhanced glucose metabolism.
Despite these facts, exogenous estrogen use among 
young women as a form of  oral contraception is associat-
ed with increased rates of  intravascular thrombosis; these 
effects are particularly prominent among smokers[28-31].
Several novel markers of  atherothrombotic risk have 
emerged from epidemiological studies and might prove 
useful clinically.
Homocysteine
Hyperhomocystinemia is linked to atherosclerosis. The 
mechanisms that account for these effects remain un-
certain but may include endothelial toxicity, accelerated 
oxidation of  LDL-C, impairment of  endothelial-derived 
relaxing factor, and reduced flow-mediated arterial vasodi-
lation[32].
Fibrinogen
Plasma fibrinogen critically influences platelet aggrega-
tion and blood viscosity, interacts with plasminogen 
binding, and in combination with thrombin mediates the 
final step in clot formation. In addition, fibrinogen asso-
ciates positively with age, obesity, smoking, diabetes, and 
LDL-C and inversely with HDL-C, alcohol use, physi-
cal activity, and exercise level. Several studies consider 
fibrinogen an independent marker of  risk for coronary 
heart disease[33-35].
Lp(a)
The normal function of  Lp(a) is unknown; the close 
homology between Lp(a) and plasminogen has raised 
the possibility that this unusual lipoprotein may inhibit 
endogenous fibrinolysis by competing with plasminogen 
for binding on the endothelial surface. More recent data 
demonstrate accumulation of  Lp(a) and co-localization 
with fibrin within atherosclerotic lesions, both in stable 
patients and among those with unstable angina pectoris. 
Apo(a) may also induce monocyte chemotactic activity 
in the vascular endothelium, whereas Lp(a) may increase 
release of  PAI. Thus, several mechanisms may con-
tribute to a role for Lp(a) in atherothrombosis. As yet, 
many studies have not established the importance of  
Lp(a) as a marker for all future cardiovascular events or 
whether an increased risk is restricted to those with the 
highest levels or with an absence of  other traditional 
risk factors[34-36].
Markers of fibrinolytic function
A role for either t-PA or PAI-1 in the development of  
venous thrombosis remains controversial. In contrast, 
a highly consistent series of  studies have linked ab-
normalities of  fibrinolysis to increased risk of  arterial 
thrombosis. Finally, several studies indicate that levels of  
D-dimer also predict myocardial infarction, peripheral 
atherothrombosis, and recurrent coronary events. De-
spite these data, the clinical use of  fibrinolytic markers 
to determine coronary risk may offer little marginal value 
(Figure 1)[37,38].
Markers of inflammation and infection
Recently, interest has increased in the possibility that 
infections, and perhaps chronic infection, may cause 
atherosclerosis. Inflammation characterizes all phases 
of  atherosclerosis from foam cell formation to plaque 
progression and rupture.
In fact, there are a lot of  data related to this issue; 
atherosclerotic lesions are heavily infiltrated by cellular 
components associated with inflammation, especially 
lymphocytes [T cells of  both the helper (CD4+) type 
and cytotoxic/suppressor (CD8+) immunologically ac-
tivated type], macrophages, and foam cells. It is evident 
that plaque complexities, especially intraplaque hemor-
rhages, are connected with the intensity of  inflammation. 
Several studies have shown a link between baseline 
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Figure 1  Relationship of the fibrinolytic factors in humans.
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elevations of  CRP, or other acute phase proteins, and 
the risk of  future cardiac events, and the evaluation of  
this marker of  infection and inflammation may be of  
importance for an effective prevention of  cardiovascular 
events[21-28].
However, the potential mechanisms for infection-
induced atherosclerosis remain speculative. 
Inflammation may promote the process by acting 
both directly and indirectly. Infection could indirectly 
influence this process without infiltrating the artery 
wall. Host defenses to extravascular infections usually 
elicit proinflammatory cytokines and stimulate increased 
expression of  cellular adhesion molecules, enhancing 
leukocyte adhesion. These cytokines could promote a 
second wave or “echo” from inflammatory cells already 
at sites of  atherogenesis, such as arterial wall cells or 
macrophages. Circulating microbial products such as 
endotoxin can also produce an echo. Similarly, cytokines 
induced by extravascular infection [specifically inter-
leukin (IL)-6] characteristically elicit hepatic synthesis of  
acute-phase reactants, some of  which might promote 
atheromata complicated by thrombosis. Accordingly, 
levels of  the acute-phase reactant fibrinogen correlate 
prospectively with risk for coronary events, and plas-
minogen activator inhibitor can promote clot stability by 
interfering with fibrinolysis. However, direct infection of  
the arterial wall could promote evolution of  atheroscle-
rotic lesions or precipitate acute cardiovascular events as 
suggested by histological findings in unstable coronary 
plaques, evidence of  systemic release of  thromboxanes 
and leukotrienes, and the presence of  activated circulat-
ing leucocyte[15,39].
The earliest lesions of  atherogenesis, consisting of  al-
tered endothelial permeability (endothelial dysfunction), 
can be induced by hemodynamic forces, by a variety of  
vasoactive substances, by mediators from blood cells, 
and directly from risk factors for atherosclerosis, with 
resulting arterial intimal accumulations of  leukocytes, 
foam cells (primarily lipid-laden macrophages) and T 
lymphocytes intermixed with smooth muscle cells. After 
crossing the surface of  the endothelium, the leukocytes 
accumulate within the intima. As the process continues, 
monocytes are converted to activated macrophages and 
take up oxidized LDL particles, thus becoming foam 
cells. The formation and accumulation of  foam cells 
within the intima create the fatty streaks of  atheroscle-
rotic lesions. If  the precipitating risk factors or offend-
ing agents are not removed, this process continues and 
leads to complex lesions. These complex lesions contain 
layers of  smooth muscle, connective tissues, macro-
phages, and T lymphocytes. The presence of  activated 
T lymphocytes in the atherosclerotic plaque suggests a 
local immune response, and it has been postulated that 
such a response may be directed against local antigens 
in the plaque. Activated T lymphocytes secrete growth 
factors and cytokines that may affect other cell types and 
the process of  atherosclerosis. Interleukins, complement 
factor fragments, and tumour necrosis factors (TNF) 
can enhance monocyte adhesiveness and chemotaxis and 
so form an amplification mechanism for recruitment of  
further monocytes into the lesion. Following endothe-
lial adhesion and transmigration into the arterial intima, 
these cells express markers of  activation. Furthermore, 
released mitogens, such as macrophage derived growth 
factor, may play a key role in smooth muscle cell migra-
tion and subsequent proliferation and hence the progres-
sion of  plaques. Activation of  circulating leucocytes may 
be facilitated at the endothelium covering an atheroscle-
rotic plaque, with upregulation of  adhesion molecules 
and tethering of  circulating cells. These inflammatory re-
sponses may further promote the infiltration of  activated 
leucocytes into the atherosclerotic lesion, which in turn 
may directly activate smooth muscle cells, macrophages, 
and T cells inside the vessel wall. Lesional macrophages 
produce proteolytic enzymes, including members of  the 
metalloproteinase family, which contribute to weakness 
of  the protective fibrous cap of  the plaque and hence 
promote the propensity of  those plaques to rupture and 
trigger thrombosis. Over time, fibrous caps, consisting 
of  smooth muscle, collagen, and elastic fibers, form to 
cover the complex lesions and intrude into the arterial 
wall. Along with impeding blood flow in the lumen, 
these fibrous plaques may rupture, causing thrombus 
formation, plaque progression, or death.
Raised concentrations of  LDL and possibly Lp(a) 
may attract monocytes to adhere to endothelium and 
induce their transformation into macrophages. The pro-
inflammatory effects of  oxidised LDL involve peroxides 
and other reactive oxygen intermediates generated by 
the oxidation of  LDL. These molecules activate nuclear 
transcription factor κB (NF-κB), which plays a key role 
in the orchestration of  inflammatory and immune re-
sponses by controlling the transcription of  the genes 
encoding several of  the adhesion molecules, ILs, TNFα, 
class Ⅱ antigen, and antibodies. NF-κB recognises vari-
ous activators, among which are the proinflammatory 
cytokines and CRP[38-41].
Most important is the role of  cytokines such as TNFα 
or IL-1 isoforms, which can stimulate the expression of  
IL-6, IL-8, and leucocyte-platelet adhesion molecules such 
as ICAM-1. These cytokines are produced by neutrophils 
and macrophages which are located in atheromatous 
plaques. They may be derived from non-vascular sources 
and reflect generalised inflammatory states, such as chron-
ic infection, which have been linked to atherogenesis and 
its clinical manifestations. The contribution of  vascular 
and extravascular sources of  inflammatory cytokines may 
vary between individuals. Primary cytokines (TNFα, IL-1) 
stimulate the production, by endothelial and other cells, 
of  adhesion molecules, procoagulants, and other media-
tors that may be released in soluble form into circulating 
blood. Primary cytokines also stimulate the production of  
messenger cytokine, IL-6, which induces expression of  
hepatic genes encoding acute phase reactants found in the 
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blood, including CRP and serum amyloid A. Moreover, 
CRP may activate complement and thus participate in sus-
taining inflammation. Serum amyloid A can bind to HDL 
particles, perhaps rendering them less protective against 
vascular inflammation[1-12].
Inflammatory cytokines modulate the homeostatic 
properties of  the endothelium. The local effects of  in-
flammatory cells on digestion of  the fibrous cap lead 
to plaque disruption and thrombus formation. Tissue 
factor is normally expressed in exposed intima and ac-
tivates factor Ⅶ which in turn activates factors Ⅸ and 
Ⅹ. Collagen in exposed intima binds von Willebrand 
factor, which mediates platelet adherence by binding 
to the glycoprotein Ⅰb/Ⅴ/Ⅸ platelet surface receptor 
complex under high shear stress conditions. Von Wil-
lebrand factor itself  is the carrier protein for factor Ⅷ, 
an essential component of  the amplifying mechanism of  
the factor Ⅹ-Ⅹa conversion. Furthermore, platelets acti-
vated by adhesion then adhere to other platelets through 
the glycoprotein Ⅱb/Ⅲa receptor and its ligand, von 
Willebrand factor and fibrinogen. Such activated plate-
lets release PAI-1, which locally inhibits the fibrinolytic 
mechanism[39,40].
Inflammation may promote thrombosis by acting 
both locally and systemically. Local mechanisms include 
the cytokine-stimulated expression of  tissue factor by 
endothelial cells and macrophages. Indirectly, inflamma-
tion may act locally to induce thrombosis by weakening 
the fibrous cap of  the atheromatous plaque, leading to 
plaque rupture. However, this role of  inflammation, and 
specifically the role of  macrophages, remains controver-
sial. Inflammation can affect systemic hemostatic activity 
via IL-6-mediated stimulation of  hepatocytes to produce 
acute phase reactants. These include certain coagulation 
factors, such as increased levels of  fibrinogen and PAI-1, 
which induce a prothrombotic state. An enhanced 
CD40L-CD40 interaction also promotes thrombotic 
activity by enhancing tissue factor expression in macro-
phages and through the direct regulation of  endothelium 
procoagulant activity. Intravascular fibrinolysis induced 
by tissue type plasminogen activator may contribute to 
atherosclerosis by inducing P-selectin and platelet acti-
vating factor, as well as contributing to plaque rupture 
by activating metalloproteinases. Oxidised LDL also 
induces tissue factor expression in macrophages and 
decreases the anticoagulant activity of  the endothelium 
by interfering with thrombomodulin expression and in-
activating tissue factor pathway inhibitor. Its expression 
is upregulated in circulating and endothelium adher-
ent monocytes, and tissue factor has been found to be 
increased in coronary tissue of  the culprit lesion from 
patients with unstable angina.
It is also now accepted that platelets may promote 
inflammatory responses. Studies have shown that 
activated platelets may mediate the homing of  leucocytes 
by interaction with the subendothelial matrix under shear 
stresses that do not allow neutrophil adhesion. They may 
also contribute to the oxidative modification of  LDL, 
provide a source of  lipids for foam cell generation, and 
contribute to smooth muscle cell proliferation[40]. 
It is now known that acute cardiovascular events are 
linked with a non-stenotic, but a vulnerable plaque. The 
difference between the mature and the unstable plaque is 
related to both core and fibrous cap. The former consist 
of  two main components, a soft lipid-rich atheromatous 
“gruel” and hard collagen-rich sclerotic tissue. The latter 
contain a core of  soft atheromatous gruel that is separated 
from the vascular lumen by a thin cap of  fibrous tissue. 
The fibrous cap is infiltrated by foam cells indicating 
ongoing disease activity. Such a thin and macrophage-
infiltrated cap is probably very weak and vulnerable, 
and it can indeed be disrupted nearby, explaining why 
erythrocytes can be seen in the gruel just beneath the 
macrophage-infiltrated cap. Sclerosis is relatively innocuous 
because fibrous tissue appears to stabilize plaques, 
protecting them against disruption. In contrast, the usually 
less voluminous atheromatous component is the more 
dangerous component, because the soft atheromatous gruel 
destabilizes plaques, making them vulnerable to rupture, 
whereby the highly thrombogenic gruel is exposed to the 
flowing blood, leading to thrombosis - a potentially life-
threatening event.
The risk of  plaque disruption is related to intrinsic 
properties of  individual plaques (their vulnerability) and 
extrinsic forces acting on plaques (rupture triggers). 
Plaque disruption occurs most frequently where the 
fibrous cap is thinnest, most heavily infiltrated by foam 
cells, and therefore weakest. The vulnerability to rupture 
depends on size and consistency of  the atheromatous 
core, thickness and collagen content of  the fibrous cap 
covering the core, inflammation within the cap and the 
cap “fatigue” caused by cyclic stretching, compression, 
bending, flexion, shear, and pressure fluctuations. 
Regarding the cap during inflammation, macrophages 
play an important role as they are capable of  degrading 
extracellular matrix by phagocytosis or by secreting 
proteolytic enzymes such as plasminogen activators 
and a family of  MMPs such as collagenases, gelatinases, 
and stromelysins that may weaken the fibrous cap, 
predisposing it to rupture, and also promoting thrombin 
generation and luminal thrombosis through the tissue 
factor pathway. Neutrophils are also capable of  destroying 
tissue by secreting proteolytic enzymes, but neutrophils 
are rare in intact plaques. They may occasionally be 
found in disrupted plaques beneath coronary thrombi, 
probably entering these plaques shortly after disruption, 
and neutrophils may also migrate into the arterial wall 
shortly after reperfusion of  occluded arteries in response 
to ischemia/reperfusion. The rupture of  a cap is linked, 
presumably, with digestion by macrophages but also with 
senescense or apoptosis of  smooth muscle cells caused 
by inflammatory cytokines.
Coronary plaques are constantly stressed by a variety 
of  biomechanical and hemodynamic forces that may 
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precipitate or “trigger” disruption of  vulnerable plaques. 
The circumferential wall tension (tensile stress) caused 
by the blood pressure establishes a stress which is redis-
tributed to adjacent structures and may be concentrated 
at critical points. The consistency of  the gruel may be 
important for this stress redistribution, as indeed are the 
characteristics of  the cap; the thinner the fibrous cap, the 
higher the stress that develops within it. Furthermore, 
mechanical shear stresses may develop in plaques at the 
interface between tissues of  different stiffness, resulting, 
for example, in shear failure, calcified plates and adjacent 
noncalcified tissue[29,30].
Plaque disruption may occur when there are increases 
in the intraplaque pressure, caused by vasospasm, bleeding 
from vasa vasorum, plaque edema, and/or collapse of  
compliant stenoses. Vasospasm reduces the circumferential 
tension in fibrous caps by narrowing the lumen (Laplace’s 
law). Nevertheless, spasm could theoretically rupture 
plaques by compressing the atheromatous core, “blowing” 
the fibrous cap out into the lumen. Bleeding and/or 
transudation (edema) into plaques from the thin-walled 
new vessels originating from vasa vasorum and frequently 
found at the plaque base could theoretically increase the 
intraplaque pressure, with resultant cap rupture from the 
inside. High-grade stenosis may be subjected to strong 
compressive forces due to the accelerated velocities in 
the throat. Collapse of  severe but compliant stenoses 
due to negative transmural pressures may produce highly 
concentrated compressive stresses from buckling of  the 
wall with bending deformation, preferentially involving 
plaque edges, and theoretically, this could contribute to 
plaque disruption. 
Another factor important for the rupture is the 
propagating pulse wave during the cardiac cycle that 
causes changes in lumen size and shape with deformation 
and bending of  plaques, and particularly of  eccentric 
plaques[12-15].
Onset of  acute coronary syndromes does not occur 
at random; in fact, a large fraction appear to be triggered 
by external factors or conditions such as emotional 
stress, vigorous exercise or cold. The pathophysiological 
mechanisms responsible for the nonrandom and (appar-
ently often) triggered onset of  infarction are unknown 
but probably related to (1) plaque disruption, most likely 
caused by surges in sympathetic activity with a sudden 
increase in blood pressure, pulse rate, heart contraction, 
and coronary blood flow; (2) thrombosis, occurring on 
previously disrupted or intact plaques when the systemic 
thrombotic tendency is high because of  platelet hyperag-
gregability, hypercoagulability, and/or impaired fibrino-
lysis; and (3) vasoconstriction, occurring locally around a 
coronary plaque or generalized[23-25].
The possibility that various microbial agents may 
trigger a cascade of  reactions leading to inflammation, 
atherogenesis, and thrombotic events in the vascular 
system has been raised in the last two decades. Chronic 
infection with various agents, both bacteria and viruses, 
such as Chlamydia pneumoniae (C. pneumoniae), Cytomegalovirus 
(CMV), HSV, Helicobacter pylori (H. pylori), Mycoplasma 
pneumoniae, anaerobic periodontal organisms, etc., has been 
implicated in the pathogenesis of  CAD. Specific agents 
have been proposed as direct initiators or accelerators of  
atherosclerosis, through nonspecific stimulation of  the 
inflammatory cascade. However, the role of  these infection 
agents must be proven; there are often confounding 
factors which should be carefully considered, although it is 
quite plausible that infections may potentiate the action of  
traditional risk factors.
C. pneumoniae
C. pneumoniae is an important respiratory pathogen asso-
ciated with 5% to 10% of  community-acquired cases of  
pneumonia, pharyngitis, bronchitis, and sinusitis. It is an 
obligatory intracellular bacterium that has the tendency 
to cause persistent infection, and may drive a chronic 
inflammatory reaction in coronary vasculature or other 
tissues. C. pneumoniae has been proposed as an etiologic 
factor for atherosclerosis, contributing either directly or 
indirectly, by modifying traditional risk factors[34-40].
In particular, cytokines produced by C. pneumoniae-
infected macrophages, located in coronary atherosclerotic 
plaques, may trigger an ongoing inflammatory response, 
and thus an increased prothrombotic state and smooth 
muscle cell proliferation, all of  which favor atherothrom-
botic complications and restenosis after stenting. Lines 
of  evidence associating C. pneumoniae with atheroscle-
rosis include seroepidemiologic studies, direct detec-
tion of  bacterial components in atherosclerotic lesions 
by polymerase chain reaction or electron microscopic 
studies, occasional isolation of  viable organisms from 
coronary and carotid atheromatous tissue, and in vitro and 
animal experiments. The strongest evidence associating 
C. pneumoniae with atherosclerotic cardiovascular disease 
has been detection of  bacterial components in athero-
sclerotic lesions. C. pneumoniae appears to have a tropism 
for atheromata. In addition, it is rarely found in normal 
arteries[34-40]. 
C. pneumoniae may infect circulatory components, 
which may attach to the endothelium and smooth 
muscle cells and kill them by apoptosis. The probable 
molecular mechanism of  atherosclerosis pathogenesis 
can be explained by up-regulation of  expression of  
heat shock protein 60 (HSP-60) by C. pneumoniae 
infection, which induces production of  cytokines such 
as TNF-α, IL-1β and IL-6, and MMPs by macrophages. 
Furthermore, C. pneumoniae could lead to elevation of  
CRP and contribute to instability or progression of  
atherosclerotic plaques. The bacterium replicates in 
endothelial and smooth muscle cells and macrophages, 
and it can activate CD4+ and CD8+ T lymphocytes. 
C. pneumoniae initiates inflammatory activation via the 
NF-κB pathway, resulting in increased expression of  
vascular cell adhesion molecule-1, enhanced recruitment 
of  inflammatory leukocytes to the vessel wall, impaired 
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activity of  endothelial nitric oxide, increased platelet 
adhesion to endothelial cells and procoagulant activity in 
endothelial cells, as well as causing oxidation of  LDL-C. 
Therefore, chronic infection may contribute to the 
risk of  CHD by initiating a high level of  immunologic 
activity, by raising triglyceride levels and decreasing 
HDL levels, and by increasing the concentrations of  
acute-phase reactants such as fibrinogen, CRP, and sialic 
acid.
Specific microbial products such as lipopolysac-
charides, heat-shock proteins, or other virulence factors 
might act locally at the level of  the artery wall to poten-
tiate atherosclerosis in infected lesions. Extravascular 
infection might also influence the development of  ath-
eromatous lesions and provoke their complication. For 
example, circulating endotoxin or cytokines produced 
in response to a remote infection can act locally at the 
level of  the artery wall to promote the activation of  
vascular cells and of  leukocytes in pre-existing lesions, 
producing an “echo” at the level of  the artery wall of  a 
remote infection. Also, the acute phase response to an 
infection in a nonvascular site might affect the incidence 
of  thrombotic complications of  atherosclerosis by in-
creasing fibrinogen or PAI-1 levels or otherwise altering 
the balance between coagulation and fibrinolysis. Such 
disturbance in the prevailing prothrombotic/fibrinolytic 
balance may critically influence whether a given plaque 
disruption will produce a clinically inapparent, transient 
or nonocclusive thrombus, or sustained and occlusive 
thrombi that could cause an acute coronary event. Acute 
infections might also produce hemodynamic alterations 
that could trigger coronary events such as tachycardia; 
increased metabolic demands of  fever could augment 
the oxygen requirements of  the heart, precipitating isch-
emia in an otherwise compensated individual. Infectious 
processes, either local in the atheroma or extravascular, 
might aggravate atherogenesis, particularly in preexisting 
lesions or in concert with traditional risk factors. 
The presence of  C. pneumoniae in atherosclerotic le-
sions raises the possibility that antibiotic treatment might 
have a favourable effect on the course of  CAD. However, 
a few large randomized antibiotic trials have not shown 
any beneficial effect of  long term antibiotic therapy (azi-
thromycin and rifampin) suggesting that large randomized 
antibiotic trials may not show clinical benefit in patients 
with established acute or chronic CAD. After failure of  
antibiotic trials, it was postulated that C. pneumoniae has 
a pathogenetic role in the early development of  athero-
sclerosis. It is possible, therefore, that infection with 
C. pneumoniae plays a part in the initiation of  atherosclero-
sis early on in life; however, once plaque and inflammation 
are established, antichlamydial antibiotics cannot alter the 
progression of  coronary disease[34-42].
Other infectious agents
Specific infectious agents other than C. pneumoniae 
have the potential to play a role in atherosclerosis as 
demonstrated by experimental models, the presence of  
organisms within plaques and inflammatory cells, and by 
seroepidemiologic associations. 
Several investigators suggested a role for other 
bacteria and viruses in cardiovascular disease such as oral 
infections caused by Porphyromonas gingivalis, Bacteroides 
forsythus, Campylobacter rectus, Fusobacterium nucleatum, 
Treponema spp., and Prevotella species. Like C. pneumoniae, 
oral bacteria might affect atherosclerosis through direct 
invasion of  vascular endothelial cells or indirectly 
through products that stimulate proinflammatory and 
prothrombotic functions of  vascular cells.
The literature linking H. pylori, HIV, HSV-1, and HSV-2 
to atherogenesis is less extensive than for C. pneumoniae 
or CMV[12]. CMV, a herpes-family DNA virus, is a com-
mon human pathogen and a candidate atherogenic 
organism. CMV can also accelerate atherosclerosis in 
animal models. Infection may induce a systemic inflam-
matory response that promotes atherosclerosis. CMV 
may contribute to CAD by several mechanisms, includ-
ing impaired fibrinolysis, increased Lp(a), enhanced pro-
coagulant activity, and upregulation of  the macrophage 
oxidized LDL scavenger receptor. CMV can inactivate 
p53, an apoptosis-related protein, facilitating excessive 
proliferation of  vascular smooth muscle cells[38].
The presence of  any chronic bacterial infection (e.g. 
respiratory, urinary, dental, or other) increases consider-
ably the risk of  developing atherosclerosis[17]. H. pylori, 
the etiologic organism of  peptic ulcer disease, has also 
received attention as a potential pathogen in atheroscle-
rosis, although the early positive serologic associations 
have not been confirmed. H. pylori organisms have not 
been demonstrated in atherosclerotic plaques, nor have 
animal models demonstrated a pathologic role. How-
ever, H. pylori infection can increase CRP and fibrinogen 
levels and promote platelet aggregation. Thus, a role for 
H. pylori in atherogenesis also remains to be established[39,40].
CONCLUSION
The best way to prevent cardiovascular disease is the 
prevention of  atherosclerosis and its development 
through removal of  risk factors. Statins are the best ther-
apeutic option to modulate inflammation, in fact several 
studies have demonstrated their anti-inflammatory, anti-
oxidant and plaque-stabilizing effects in addition to their 
cholesterol-lowering effects. Statin treatment for global 
cardiovascular risk prevention is indicated and must be 
proposed in high risk patients. In addition, treatments 
for hypertension, diabetes, weight loss, exercise and 
smoking cessation are vitally important measures for 
cardiovascular risk reduction.
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